Study of two drugs before stem cell transplant for Ph+ ALL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two targeted drugs, Olverembatinib and Inotuzumab Ozogamicin, given as consolidation therapy before a stem cell transplant for people with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who did not achieve a deep response after initial chemotherapy. The goal is to see if this approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have Ph+ ALL and your leukemia cells have a protein called CD22 on their surface.
- Your first round of chemotherapy plus a targeted drug did not get rid of all the leukemia cells (measured by a sensitive test).
- You are healthy enough for a stem cell transplant, with good liver, kidney, pancreas, and heart function.
- You do not have active infections like HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy called Olverembatinib given after a donor stem cell transplant (allo-HSCT) for a type of leukemia called Ph+ ALL. The drug is used either to prevent relapse or to treat early signs of the disease, and it may help keep you in remission longer.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This Phase 2 trial tests olverembatinib plus blinatumomab for Philadelphia chromosome–positive (Ph+) ALL that is newly diagnosed. It aims to see how well this combination works and how safe it is for people who have not yet had standard leukemia medicines.
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
This trial tests a combination of three drugs (venetoclax, olverembatinib, and prednisone) for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combination is safe and effective.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.